ArticleBMC infectious diseases2025
Coexistence of carbapenem resistance and hypervirulence in clinical Klebsiella pneumoniae isolates: a molecular and phenotypic analysis.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Short-Term Within-Host Genomic Diversity and Clone Turnover of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Detection of hypervirulence genes in carbapenem resistant Klebsiella pneumoniae from cancer patients at a tertiary referral hospital in Nepal.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenem-resistant hypervirulent Klebsiella pneumoniae (CRhvKp) is increasingly recognized as the predominant nosocomial pathogen in healthcare environments.
objectiveThis study aims to investigate the prevalence, antibiotic resistance patterns, and molecular characteristics of CRhvKp in Egypt.
methodsOut of 150 non-duplicate clinical isolates collected from a hospital in Egypt, 63 were identified as K. pneumoniae via biochemical tests and matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS). The CRKp isolates were identified using the VITEK
resultsAmong the 63 K. pneumoniae isolates, 30 were identified as CRKp, and all exhibited multidrug resistance (MDR). CRKp was classified as 66.7% for CRhvKp and 33.3% for CR-non-hvKp. The presence of various virulence genes in CRhvKp and CR-non-hvKp samples was observed as follows: fimH (75% and 60%), mrkD (100% and 90%), entB (80% and 90%), irp2 (85% and 90%), wabG (90% and 60%), and uge (40% and 60%). The existence of carbapenemase genes in CRhvKp and CR-non-hvKp samples was observed as follows: bla
conclusionOur study identified a significant percentage of MDR CRhvKp and CR-non-hvKp isolates harboring different carbapenemases, which sparked substantial concern. Herein, we highlight the concerning rapid increase of CRhvKp in Egypt. Hence, continued countrywide are surveillance is crucial to clarify the prevalence rate of these CRhvKp in Egypt.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.